Iron Deficiency Anemia Therapeutics Market Shows Promise with Emerging Therapies
• The iron deficiency anemia (IDA) therapeutics market is expected to grow, with a market size of around USD 1,400 million in the 7MM in 2023.
• Emerging therapies like MPB-1514 (MegaPro Biomedical) and IDAX (Nemysis) show promise in improving treatment options for IDA patients.
• Clinical trials are underway to evaluate the efficacy of novel oral iron formulations like IHAT for increasing serum ferritin levels.
• Oral iron therapy remains the first-line treatment, but intravenous iron products like Monoferric (Pharmacosmos) offer alternatives.
© Copyright 2025. All Rights Reserved by MedPath